Axogen, Inc.
No enriched coverage for $AXGN in the last 7 days.
No SEC Form 4 filings for $AXGN in the last 30 days.
Axogen's Chief Innovation Officer, Erick Wayne DeVinney, sold 5,221 shares of common stock for approximately $171,457 and disposed of 2,870 shares to cover tax obligations. Despite the stock's recent retreat, analysts maintain a bullish outlook with price targets between $39 and $43. The company also recently surpassed Q4 2025 earnings and revenue expectations.
Axogen (AXGN) reported strong 21% revenue growth for Q4 2025, but missed EPS expectations, leading to an 8% share decline and highlighting margin pressures. The company is transitioning to a regulated biologics platform with Avance FDA approval, aiming for sustainable growth, 18%+ revenue guidance, and positive free cash flow in 2026. Despite a hold rating due to a stretched valuation, the company anticipates normalization of gross margin compression as biologics pricing and payer coverage expand.
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of Caterpillar Inc ( NYSE:CAT ) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results.
